These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32562359)

  • 21. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
    Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
    Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM
    Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Michishita I
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):320-6. PubMed ID: 23324995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.
    Kohli-Lynch CN; Bellows BK; Zhang Y; Spring B; Kazi DS; Pletcher MJ; Vittinghoff E; Allen NB; Moran AE
    J Am Coll Cardiol; 2021 Nov; 78(20):1954-1964. PubMed ID: 34763772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
    Spahillari A; Zhu J; Ferket BS; Hunink MGM; Carr JJ; Terry JG; Nelson C; Mwasongwe S; Mentz RJ; O'Brien EC; Correa A; Shah RV; Murthy VL; Pandya A
    JAMA Cardiol; 2020 Aug; 5(8):871-880. PubMed ID: 32401264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I
    Am J Cardiol; 2013 Jun; 111(11):1570-5. PubMed ID: 23497779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis.
    Morton JI; Marquina C; Lloyd M; Watts GF; Zoungas S; Liew D; Ademi Z
    Pharmacoeconomics; 2024 Jan; 42(1):91-107. PubMed ID: 37606881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
    Xie W; Song Y; Qin X; Jin P
    Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
    Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
    Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
    Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of statin therapy among people living with HIV.
    Boettiger DC; Kerr S; Chattranukulchai P; Siwamogsatham S; Avihingsanon A
    AIDS; 2021 Mar; 35(4):567-574. PubMed ID: 33252492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.
    Conly J; Clement F; Tonelli M; Hemmelgarn B; Klarenbach S; Lloyd A; McAlister FA; Husereau D; Wiebe N; Au F; Manns B;
    CMAJ; 2011 Nov; 183(16):E1180-8. PubMed ID: 21989469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
    Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; King JB; Bellows BK; Tajeu GS; Derington CG; Johnson J; Andrade K; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
    JAMA Netw Open; 2022 Feb; 5(2):e2148172. PubMed ID: 35157055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.